GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Price-to-Free-Cash-Flow

Immunovant (Immunovant) Price-to-Free-Cash-Flow : N/A (As of May. 02, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant Price-to-Free-Cash-Flow?

As of today (2024-05-02), Immunovant's share price is $28.135. Immunovant's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.58. Hence, Immunovant's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Immunovant's Price-to-Free-Cash-Flow or its related term are showing as below:

IMVT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.795
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Immunovant's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.33. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.58.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -7.40% per year.

During the past 5 years, Immunovant's highest 3-Year average Free Cash Flow per Share Growth Rate was -7.40% per year. The lowest was -7.40% per year. And the median was -7.40% per year.


Immunovant Price-to-Free-Cash-Flow Historical Data

The historical data trend for Immunovant's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Price-to-Free-Cash-Flow Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
- - - - -

Immunovant Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovant's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Immunovant's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Immunovant's Price-to-Free-Cash-Flow falls into.



Immunovant Price-to-Free-Cash-Flow Calculation

Immunovant's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=28.135/-1.576
=N/A

Immunovant's Share Price of today is $28.135.
Immunovant's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.58.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Immunovant  (NAS:IMVT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Immunovant Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Immunovant's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant (Immunovant) Business Description

Traded in Other Exchanges
N/A
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
William L. Macias officer: Chief Medical Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett officer: Chief Financial Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mark S. Levine officer: Chief Legal Officer 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Jay S Stout officer: Chief Technology Officer C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Rita Jain officer: Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018